FQFeng Qian

Feng Qian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Feng Qian has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Munir Hussain

    Drug Product Science & Technology, Bristol-Myers Squibb Co., New Brunswick, USA

    4 shared publications
  • Ronald L. Smith

    Merck Research Laboratories, Merck & Co., Inc., West Point, PA 19486-0004, United States

    3 shared publications
  • Sridhar Desikan

    Biopharmaceutics and Analytical R&D, Bristol-Myers Squibb India Private Limited, Biocon Park, Jigani Link Road, Bommasandra IV, Bangalore 560099, India

    3 shared publications
  • Jing Tao

    Drug Product Science & Technology, Bristol-Myers Squibb Co., New Brunswick, USA

    2 shared publications
  • Nina Ni

    Biopharmaceutics R&D, Bristol-Myers Squibb Company, New Brunswick, NJ 08903, United States

    2 shared publications
  • Raja Haddadin

    Drug Product Science & Technology, Bristol-Myers Squibb Co., New Brunswick, USA

    2 shared publications

Latest Publications

  • Solution Behavior of PVP-VA and HPMC-AS-Based Amorphous Solid Dispersions and Their Bioavailability Implications

    by Feng Qian, Jennifer Wang, Ruiling Hartley, Jing Tao, Raja Haddadin, Neil Mathias, Munir Hussain

    Purpose To identify the mechanism behind the unexpected bio-performance of two amorphous solid dispersions: BMS-A/PVP-VA and BMS-A/HPMC-AS. Methods Solubility of crystalline BMS-A in PVP-VA and HPMC-AS was measured by DSC. Drug-polymer interaction parameters were obtained by Flory-Huggins model fitting. Drug dissolution kinetics of spray-dried dispersions were studied under sink and non-sink conditions. BMS-A supersaturation was studied in the presence of pre-dissolved PVP-VA and HPMC-AS. Potency and crystallinity of undissolved solid dispersions were determined by HPLC and DSC. Polymer dissolution kinetics were obtained by mass balance calculation. Bioavailability of solid dispersions was assessed in dogs. Results In solid state, both polymers are miscible with BMS-A, while PVP-VA solublizes the drug better. BMS-A dissolves similarly from both solid dispersions in vitro regardless of dissolution method, while the HPMC-AS dispersion performed much better in vivo. At the same concentration, HPMC-AS is more effective in prolonging BMS-A supersaturation; this effect was negated by the slow dissolution rate of HPMC-AS. Further study revealed that fast PVP-VA dissolution resulted in elevated drug loading in undissolved dispersions and facilitated drug recrystallization before complete release. In contrast, the hydrophobicity and slower HPMC-AS dissolution prevented BMS-A recrystallization within the HPMC-AS matrix for >24 h. Conclusions The lower bioavailability of PVP-VA dispersion was attributed to BMS-A recrystallization within the undissolved dispersion, due to hydrophilicity and fast PVP-VA dissolution rate. Polymer selection for solid dispersion development has significant impact on in vivo performance besides physical stability.


  • Is a distinctive single Tg a reliable indicator for the homogeneity of amorphous solid dispersion?

    by Feng Qian, Jun Huang, Qing Zhu, Raja Haddadin, John Gawel, Robert Garmise, Munir Hussain


  • Sustained release subcutaneous delivery of BMS-686117, a GLP-1 receptor peptide agonist, via a zinc adduct

    by Feng Qian, Nina Ni, Lori S. Burton, Yue Fen Wang, Sridhar Desikan, Munir Hussain, Ronald L. Smith


  • Formation of Zinc–Peptide Spherical Microparticles During Lyophilization from tert-Butyl Alcohol/Water Co-solvent System

    by Feng Qian, Nina Ni, Jia-Wen Chen, Sridhar Desikan, Vijay Naringrekar, Munir A. Hussain, Nancy P. Barbour, Ronald L. Smith


  • Mechanistic Investigation of Pluronic® Based Nano-crystalline Drug-polymer Solid Dispersions

    by Feng Qian, Jing Tao, Sridhar Desikan, Munir Hussain, Ronald L. Smith

    Purpose To understand the mechanism of nano-crystalline drug formation in Pluronic® (i.e., poly(ethylene oxide-block-propylene oxide) triblock copolymers) based drug-polymer solid dispersions. Materials and Methods Four polymers, Pluronic® F127, F108, F68 and PEG 8000, which have different poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) ratio and chain length, were co-spray dried with BMS-347070, a COX-2 inhibitor, to form 50/50 (w/w) drug-polymer solid dispersions. The solid dispersions were analyzed by powder X-ray diffraction (PXRD), modulated differential scanning calorimetry (mDSC), and hot-stage microscopy. Average size of drug crystallites in different polymers was calculated by the Scherrer equation based on peak-broadening effect in PXRD. Two other drug compounds, BMS-A and BMS-B, were also spray dried with Pluronic® F127, and the solid dispersions were analyzed by PXRD and mDSC. Results The average size of BMS-347070 crystallites in PEG 8000, F127, F108 and F68 polymers was 69, 80, 98 and 136 nm, respectively, and the degree of BMS-347070 crystallinity is the lowest in PEG 8000. Hot-stage microscopy showed that 50/50 drug-polymer dispersions crystallized in a two-step process: a portion of the polymer crystallizes first (Step 1), followed by crystallization of drug and remaining polymer (Step 2). The T g value of the BMS-347070/Pluronic® dispersions after Step 1 (i.e., T g1) was measured and/or calculated to be 15–26°C, and that of BMS-347070/PEG 8000 was 60°C. Solid dispersions of BMS-A and BMS-B in Pluronic® F127 have T g1 of 72 and 3°C, respectively; and PXRD showed BMS-A remained amorphous after ∼3 weeks under ambient condition, while BMS-B crystallized in F127 with an average crystallite size of 143 nm. Conclusions The size of drug crystallites in the drug-polymer solid dispersions is independent of polymer topology, but is caused kinetically by a combined effect of nucleation rate and crystal growth rate. When drug-Pluronic® solid dispersions crystallize at room temperature, that is close to the T g1 of the systems, a fast nucleation rate and a relatively slow crystal growth rate of the drug synergistically produced small crystallite size. While the much higher T g1 value of drug-PEG 8000 led to a slower nucleation rate and an even slower crystal growth rate at room temperature, therefore, small crystallite size and low drug crystallinity were observed. Results from BMS-A/Pluronic® and BMS-B/Pluronic® systems confirmed this kinetic theory.